To investigate the potential of TLR2 and TLR9 inhibition in pancreatic cancer cells and its efficacy in tumor cell death, we developed pCMV Myc NCAM1, pCMV Myc TLR2, and pCMV Myc TLR9 plasmids expressing NCAM1 intrabodies (control intrabodies) and TLR2- and TLR9-specific intrabodies. This evidence concerns the gene NCAM1 and pancreatic neoplasm.